Form 4: Regeneron Executive Neil Stahl Sells Shares to Cover Tax Obligations

Regeneron's Executive Vice President of Research and Development, Neil Stahl, sold 466 shares of company stock to cover tax obligations.

Summary

• Neil Stahl, Executive Vice President of Research and Development at Regeneron Pharmaceuticals, sold 466 shares of common stock on December 9, 2024.
• The sale was executed to cover tax obligations related to stock awards.
• Following the transaction, Mr. Stahl directly owns 49,133 shares of Regeneron stock.
• He also indirectly owns 5,849 shares through a 401(k) plan and 4,605 shares held by his spouse as trustee.

Sentiment

Score: 5

Explanation: The document reflects a neutral event, a routine stock sale by an executive for tax purposes. It doesn't indicate any positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common practice across the pharmaceutical industry.
• Many executives at comparable companies such as Amgen, Gilead, and AbbVie regularly sell shares to cover tax obligations related to stock awards.
• These transactions are typically disclosed through SEC Form 4 filings, similar to this one.

Stakeholder Impact

• The stock sale has a minimal impact on shareholders as it is a small transaction by an individual executive.
• The transaction does not affect employees, customers, suppliers, or creditors.

Key Dates

Keywords

Regeneron, Neil Stahl, stock sale, insider trading, executive compensation, tax obligations, share ownership